NOBODY WANTS TO find out they have prostate cancer. Yet the earlier it's detected, the better. The cancer is very treatable when it's discovered early; you’ll have the most treatment options, giving ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Prostate cancer is a significant global health issue, affecting millions of men worldwide and ranking as the second most common cancer in men globally. In the United States alone, it is estimated that ...

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is ...

A multicenter clinical study in Austria has shown that a new, highly precise ultrasound approach can successfully target and ...

As a physician, researcher, and biotech leader with personal experience of prostate cancer in my family, I’ve long advocated for putting patients first in our quest for medical innovation. Today, I ...

At the same time, incidence of distant-stage prostate cancer increased. (HealthDay News) — Distant-stage prostate cancer increased and mortality rates plateaued throughout California during the 2010s, ...

A study from Karl Landsteiner University of Health Sciences demonstrates that treatment with focused ultrasound (HIFU) effectively controls prostate cancer and maintains patients’ quality of ...